Cardiovascular risk factors and dementia

Howard Fillit, David T. Nash, Tatjana Rundek, Andrea Zuckerman

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Background: Dementias, such as Alzheimer's disease (AD) and vascular dementia, are disorders of aging populations and represent a significant economic burden. Evidence is accumulating to suggest that cardiovascular disease (CVD) risk factors may be instrumental in the development of dementia. Objective: The goal of this review was to discuss the relationship between specific CVD risk factors and dementia and how current treatment strategies for dementia should focus on reducing CVD risks. Methods: We conducted a review of the literature for the simultaneous presence of 2 major topics, cardiovascular risk factors and dementia (eg, AD). Special emphasis was placed on clinical outcome studies examining the effects of treatments of pharmacologically modifiable CVD risk factors on dementia and cognitive impairment. Results: Lifestyle risk factors for CVD, such as obesity, lack of exercise, smoking, and certain psychosocial factors, have been associated with an increased risk of cognitive decline and dementia. Some evidence suggests that effectively managing these factors may prevent cognitive decline/dementia. Randomized, placebo-controlled trials of antihypertensive medications have found that such therapy may reduce the risk of cognitive decline, and limited data suggest a benefit for patients with AD. Some small open-label and randomized clinical trials of statins have observed positive effects on cognitive function; larger studies of statins in patients with AD are ongoing. Although more research is needed, current evidence indicates an association between CVD risk factors-such as hypertension, dyslipidemia, and diabetes mellitus-and cognitive decline/dementia. Conclusions: From a clinical perspective, these data further support the rationale for physicians to provide effective management of CVD risk factors and for patients to be compliant with such recommendations to possibly prevent cognitive decline/dementia.118).

Original languageEnglish
Pages (from-to)100-118
Number of pages19
JournalAmerican Journal Geriatric Pharmacotherapy
Volume6
Issue number2
DOIs
StatePublished - Jun 1 2008

Fingerprint

Dementia
Cardiovascular Diseases
Alzheimer Disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Randomized Controlled Trials
Vascular Dementia
Dyslipidemias
Cognition
Antihypertensive Agents
Cognitive Dysfunction
Life Style
Diabetes Mellitus
Therapeutics
Obesity
Smoking
Placebos
Economics
Outcome Assessment (Health Care)
Exercise
Psychology

Keywords

  • Alzheimer's
  • cardiovascular risk
  • dementia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Geriatrics and Gerontology

Cite this

Cardiovascular risk factors and dementia. / Fillit, Howard; Nash, David T.; Rundek, Tatjana; Zuckerman, Andrea.

In: American Journal Geriatric Pharmacotherapy, Vol. 6, No. 2, 01.06.2008, p. 100-118.

Research output: Contribution to journalArticle

Fillit, Howard ; Nash, David T. ; Rundek, Tatjana ; Zuckerman, Andrea. / Cardiovascular risk factors and dementia. In: American Journal Geriatric Pharmacotherapy. 2008 ; Vol. 6, No. 2. pp. 100-118.
@article{f102d9ffec6044f99091cf63cfc708ec,
title = "Cardiovascular risk factors and dementia",
abstract = "Background: Dementias, such as Alzheimer's disease (AD) and vascular dementia, are disorders of aging populations and represent a significant economic burden. Evidence is accumulating to suggest that cardiovascular disease (CVD) risk factors may be instrumental in the development of dementia. Objective: The goal of this review was to discuss the relationship between specific CVD risk factors and dementia and how current treatment strategies for dementia should focus on reducing CVD risks. Methods: We conducted a review of the literature for the simultaneous presence of 2 major topics, cardiovascular risk factors and dementia (eg, AD). Special emphasis was placed on clinical outcome studies examining the effects of treatments of pharmacologically modifiable CVD risk factors on dementia and cognitive impairment. Results: Lifestyle risk factors for CVD, such as obesity, lack of exercise, smoking, and certain psychosocial factors, have been associated with an increased risk of cognitive decline and dementia. Some evidence suggests that effectively managing these factors may prevent cognitive decline/dementia. Randomized, placebo-controlled trials of antihypertensive medications have found that such therapy may reduce the risk of cognitive decline, and limited data suggest a benefit for patients with AD. Some small open-label and randomized clinical trials of statins have observed positive effects on cognitive function; larger studies of statins in patients with AD are ongoing. Although more research is needed, current evidence indicates an association between CVD risk factors-such as hypertension, dyslipidemia, and diabetes mellitus-and cognitive decline/dementia. Conclusions: From a clinical perspective, these data further support the rationale for physicians to provide effective management of CVD risk factors and for patients to be compliant with such recommendations to possibly prevent cognitive decline/dementia.118).",
keywords = "Alzheimer's, cardiovascular risk, dementia",
author = "Howard Fillit and Nash, {David T.} and Tatjana Rundek and Andrea Zuckerman",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.amjopharm.2008.06.004",
language = "English",
volume = "6",
pages = "100--118",
journal = "American Journal Geriatric Pharmacotherapy",
issn = "1543-5946",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - Cardiovascular risk factors and dementia

AU - Fillit, Howard

AU - Nash, David T.

AU - Rundek, Tatjana

AU - Zuckerman, Andrea

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Background: Dementias, such as Alzheimer's disease (AD) and vascular dementia, are disorders of aging populations and represent a significant economic burden. Evidence is accumulating to suggest that cardiovascular disease (CVD) risk factors may be instrumental in the development of dementia. Objective: The goal of this review was to discuss the relationship between specific CVD risk factors and dementia and how current treatment strategies for dementia should focus on reducing CVD risks. Methods: We conducted a review of the literature for the simultaneous presence of 2 major topics, cardiovascular risk factors and dementia (eg, AD). Special emphasis was placed on clinical outcome studies examining the effects of treatments of pharmacologically modifiable CVD risk factors on dementia and cognitive impairment. Results: Lifestyle risk factors for CVD, such as obesity, lack of exercise, smoking, and certain psychosocial factors, have been associated with an increased risk of cognitive decline and dementia. Some evidence suggests that effectively managing these factors may prevent cognitive decline/dementia. Randomized, placebo-controlled trials of antihypertensive medications have found that such therapy may reduce the risk of cognitive decline, and limited data suggest a benefit for patients with AD. Some small open-label and randomized clinical trials of statins have observed positive effects on cognitive function; larger studies of statins in patients with AD are ongoing. Although more research is needed, current evidence indicates an association between CVD risk factors-such as hypertension, dyslipidemia, and diabetes mellitus-and cognitive decline/dementia. Conclusions: From a clinical perspective, these data further support the rationale for physicians to provide effective management of CVD risk factors and for patients to be compliant with such recommendations to possibly prevent cognitive decline/dementia.118).

AB - Background: Dementias, such as Alzheimer's disease (AD) and vascular dementia, are disorders of aging populations and represent a significant economic burden. Evidence is accumulating to suggest that cardiovascular disease (CVD) risk factors may be instrumental in the development of dementia. Objective: The goal of this review was to discuss the relationship between specific CVD risk factors and dementia and how current treatment strategies for dementia should focus on reducing CVD risks. Methods: We conducted a review of the literature for the simultaneous presence of 2 major topics, cardiovascular risk factors and dementia (eg, AD). Special emphasis was placed on clinical outcome studies examining the effects of treatments of pharmacologically modifiable CVD risk factors on dementia and cognitive impairment. Results: Lifestyle risk factors for CVD, such as obesity, lack of exercise, smoking, and certain psychosocial factors, have been associated with an increased risk of cognitive decline and dementia. Some evidence suggests that effectively managing these factors may prevent cognitive decline/dementia. Randomized, placebo-controlled trials of antihypertensive medications have found that such therapy may reduce the risk of cognitive decline, and limited data suggest a benefit for patients with AD. Some small open-label and randomized clinical trials of statins have observed positive effects on cognitive function; larger studies of statins in patients with AD are ongoing. Although more research is needed, current evidence indicates an association between CVD risk factors-such as hypertension, dyslipidemia, and diabetes mellitus-and cognitive decline/dementia. Conclusions: From a clinical perspective, these data further support the rationale for physicians to provide effective management of CVD risk factors and for patients to be compliant with such recommendations to possibly prevent cognitive decline/dementia.118).

KW - Alzheimer's

KW - cardiovascular risk

KW - dementia

UR - http://www.scopus.com/inward/record.url?scp=48149111799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48149111799&partnerID=8YFLogxK

U2 - 10.1016/j.amjopharm.2008.06.004

DO - 10.1016/j.amjopharm.2008.06.004

M3 - Article

C2 - 18675769

AN - SCOPUS:48149111799

VL - 6

SP - 100

EP - 118

JO - American Journal Geriatric Pharmacotherapy

JF - American Journal Geriatric Pharmacotherapy

SN - 1543-5946

IS - 2

ER -